As of September 30, 2026, Guobang Pharma Ltd. Class A carries a market capitalization of 14.15B, placing it among publicly traded companies globally. Its enterprise value stands at 12.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 14.15B |
| Enterprise Value | 12.61B |
Guobang Pharma Ltd. Class A's next confirmed earnings release is scheduled for April 12, 2027.
| Earnings Date | 4/12/2027 |
As of September 30, 2026, Guobang Pharma Ltd. Class A has 782.35M shares outstanding.
| Shares Outstanding | 782.35M |
As of September 30, 2026, Guobang Pharma Ltd. Class A trades at a trailing price-to-earnings ratio of 22.48. The price-to-sales ratio is 2.28, and the price-to-book ratio stands at 1.66.
| PE Ratio | 22.48 |
| PS Ratio | 2.28 |
| PB Ratio | 1.66 |
| P/TBV Ratio | 1.74 |
As of September 30, 2026, Guobang Pharma Ltd. Class A trades at an EV/EBITDA multiple of 17.44 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.44 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 12.61B versus a market cap of 14.15B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 2.06 |
| EV / EBITDA | 17.44 |
| EV / EBIT | 17.44 |
As of September 30, 2026, Guobang Pharma Ltd. Class A maintains a current ratio of 2.45, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.19, indicating elevated leverage, while an interest coverage ratio of 33.00 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.45 |
| Quick Ratio | 0.98 |
| Debt / Equity | 11.19 |
| Debt / EBITDA | 1.32 |
| Interest Coverage | 33.00 |
These figures cover the twelve months ended September 30, 2026. The company generates approximately 1.44M in revenue per employee across its workforce of 4,251.00, a quick read on workforce productivity versus industry peers.
| Revenue Per Employee | 1.44M |
| Employee Count | 4,251.00 |
Over the twelve months ended September 30, 2026, Guobang Pharma Ltd. Class A recorded 89.26M in income tax expense. That works out to an effective tax rate of 12.56, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 710.58M, leaving 621.94M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 89.26M |
| Effective Tax Rate | 12.56 |
As of the close on November 17, 2026, Guobang Pharma Ltd. Class A's stock has declined approximately 4.43% over the past 52 weeks. The 50-day moving average sits at 16.18, while the 200-day moving average is 16.90.
| 52-Week Price Change | -4.43% |
| 50-Day Moving Average | 16.18 |
| 200-Day Moving Average | 16.90 |
Over the twelve months ended September 30, 2026, Guobang Pharma Ltd. Class A generated 6.13B in revenue and converted that into 621.94M in net income, yielding earnings per share of 0.80. EBITDA reached 722.94M, while operating income came in at 797.83M.
| Revenue | 6.13B |
| Gross Profit | 1.43B |
| Operating Income | 797.83M |
| Pretax Income | 710.58M |
| Net Income | 621.94M |
| EBITDA | 722.94M |
| EBIT | 722.94M |
| Earnings Per Share (EPS) | 0.80 |
As of September 30, 2026, Guobang Pharma Ltd. Class A holds 2.50B in cash and equivalents against 952.93M in total debt, resulting in a net debt position of -692.44M. Total book value stands at 8.51B, with working capital of 3.68B providing operational flexibility.
| Cash & Cash Equivalents | 2.50B |
| Total Debt | 952.93M |
| Net Debt | -692.44M |
| Equity (Book Value) | 8.51B |
| Book Value Per Share | 10.88 |
| Working Capital | 3.68B |
These figures cover the twelve months ended September 30, 2026.
| Capital Expenditures | -360.30M |
Over the twelve months ended September 30, 2026, Guobang Pharma Ltd. Class A posted a gross margin of 23.26, reflecting its pricing power and cost economics. The operating margin of 13.01 and net profit margin of 10.15 provide insight into operational efficiency.
| Gross Margin | 23.26 |
| Operating Margin | 13.01 |
| Pretax Margin | 11.59 |
| Profit Margin | 10.15 |
| EBITDA Margin | 11.79 |
Over the twelve months ended September 30, 2026, Guobang Pharma Ltd. Class A paid dividends of 0.46 per share. The dividend payout ratio of 57.03 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.51, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Guobang Pharma Ltd. Class A shareholders.
| Dividend Per Share | 0.46 |
| Payout Ratio | 57.03 |
| Shareholder Yield | 2.51 |
Guobang Pharma Ltd. Class A's most recent stock split took place on May 29, 2026 with a 5:7 split ratio.
| Last Split Date | 5/29/2026 |
| Split Ratio | 5:7 |
As of September 30, 2026, Guobang Pharma Ltd. Class A has an Altman Z-Score of 4.85, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.85 |
Already premium?